May 2nd 2024
The April 2024 cardiology month in review spotlights FDA news and top updates from the American College of Cardiology 2024 Scientific Session.
Early Aspirin Use Could Lower Mortality, Odds of Stroke in COVID-19
March 24th 2022An analysis of data from more than 110k hospitalized patients with COVID-19 suggests aspirin use on the first day of hospitalization was linked to lower odds for both in-hospital mortality and pulmonary embolism in weighted analyses.
Antiplatelet Therapy Unlikely to Improve Organ Support-Free Days in COVID-19
March 23rd 2022Data from the REMAP-CAP trial suggests use of aspirin or P2Y12 inhibitors had a low likelihood of improving organ support-free days in critically ill patients with COVID-19 within 21 days compared to no antiplatelet therapy.
Hypertriglyceridemia Increases Recurrent Stroke Risk, Despite Statin Use and Well-Controlled LDL-C
March 17th 2022An analysis of data from a prospective stroke registry suggests presence of hypertriglyceridemia was associated with a more than 2-fold increase in risk of MACE among patients with a history of acute stroke or TIA, even with adjustment for baseline LDL-C and statin use.
DOACs Could Lower Bleeding, Hemorrhage Risk vs. Warfarin in Patients with CVT
February 10th 2022An international, retrospective analysis presented at ISC 2022 provides evidence suggesting use of DOACs as a treatment for cerebral venous thrombosis was associated with similar risk of recurrent clots and death as warfarin, but a 65% lower risk of major bleeding.
FDA Approves Twice-Yearly Inclisiran (Leqvio) for Lowering Cholesterol in ASCVD, HeFH
December 22nd 2021Announced on December 22, the approval of inclisiran (Leqvio) comes nearly a year after the original PDUFA date. With approval, inclisiran becomes the first and only siRNA therapy approved to lower LDL-C with twice-yearly dosing.
Statin Discontinuation Associated with Excess MACE Events in Older Patients
December 13th 2021Data from an analysis of 67k older Danes suggests statin discontinuation corresponded with 1 excess event per 112 persons per year in a primary prevention cohort and 1 excess event per 77 persons per year in a secondary prevention cohort.
REVERSE-IT: Bentracimab Shows Promise as Fast-Acting Ticagrelor Reversal Agent
November 15th 2021Deepak Bhatt, MD, MPH, discusses the results of the interim analysis of the REVERSE-IT trial presented at AHA 2021, which indicates bentracimab provided immediate and sustained reversal of ticagrelor's antiplatelet effects in patients requiring urgent surgery or experiencing major bleeding.
Statin Use Associated with Increased Odds of Worsening Diabetes, Study Finds
October 5th 2021Using data from more than 80k matched pairs of statin users and comparators, investigators from UT Southwestern Medical Center found initiation of statin therapy was associated with an increased likelihood of diabetes progression, including risk of hyperglycemia and ketoacidosis.
Return to Healthy Weight Could Reverse Cardiovascular Risk in Obesity
September 30th 2021An analysis of NHANES data presented at EASD 2021 suggests a return to a healthy weight in patients with obesity could result in reverse some of the cardiovascular risk associated with obesity, including high blood pressure and cholesterol disorders.
Evolocumab Approved for Pediatric Patients with Heterozygous Familial Hypercholesterolemia
September 27th 2021Announced on September 24, the approval is for use as an adjunct to diet and other LDL-C-lowering therapies for reducing LDL-C in patients aged 10 years and older with heterozygous familial hypercholesterolemia.
Ticagrelor Monotherapy Reduces Bleeding Events vs DAPT with Aspirin in HBR Patients
August 30th 2021TWILIGHT-HBR suggests ticagrelor monotherapy could lower bleeding risk among patients meeting ARC-HBR criteria. Study presenter Davide Cao, MD, offers further perspective on results of the post hoc analysis.
TWILIGHT Analysis Suggests Ticagrelor Monotherapy Preferable in Concomitant Diabetes and CKD
August 30th 2021A post hoc analysis of the TWILIGHT trial suggests the effects of ticagrelor monotherapy observed in the overall trial were consistent, irrespective of diabetes and chronic kidney disease status.